A method for constructing an in vitro model of trigeminal neuralgia targeting fibrocyte and microglia interaction and a drug screening method thereof
By constructing an in vitro model targeting the interaction between fibroblasts and microglia and utilizing a specific culture medium rich in clustering proteins, the lack of disease specificity in existing technologies has been addressed, enabling efficient and accurate evaluation of trigeminal neuralgia drug screening and significantly reducing R&D costs.
Patent Information
- Application Number
- CN202610856209.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-06-15
- Publication Date
- 2026-07-17
AI Technical Summary
Existing in vitro drug screening methods lack disease specificity and cannot effectively intervene in the real pathological triggering mechanism of the arachnoid microenvironment in trigeminal neuralgia, leading to drug conversion failure.
Using an in vitro model of interaction between fibroblasts and microglia, a specific conditioned medium rich in clustering protein (CLU) was prepared to precisely activate a specific cascade pathway within microglia. Pathological paracrine stimulation of the arachnoid microenvironment was then restored using CLU-CM and Mgp_Fibroblast conditioned mediums for drug screening.
This enables precise intervention on targets in the real microenvironment of microglia, improving the disease specificity of drug screening, reducing R&D costs, and accelerating the process of new drug discovery.
Smart Images
Figure CN122405552A_ABST